Sponsors (3)
Establishes one consolidated Medicare payment and billing code for all skin substitute products from Jan 1, 2026, with CPI-U updates and an ASP reporting exemption for manufacturers.
The bill consolidates and simplifies Medicare payment for skin substitutes and aims to contain costs while preserving basic safety review, but those payment reforms risk reduced product availability, less transparency, constrained clinician choice, and potential cost‑shifts that could harm patients or suppliers.
Medicare beneficiaries with chronic, non-healing wounds would have coverage rules that better reflect clinical value, improving access to appropriate skin substitute therapies.
Medicare (and taxpayers) could see lower spending growth on skin substitutes by removing incentives for higher‑priced products and consolidating payment, reducing fiscal pressure on the program.
Medicare beneficiaries and hospitals would get simpler, more predictable consolidated payments starting Jan 1, 2026, with annual CPI‑U indexing from 2027 that preserves inflation‑linked updates for providers.
Medicare beneficiaries could face reduced availability of certain skin substitute products or higher out‑of‑pocket costs if revised reimbursement leads providers to stop using items that are no longer covered at prior rates.
Manufacturers may receive lower reimbursement under a consolidated, volume‑weighted payment, risking reduced supply, diminished incentives for innovation, or exits by smaller suppliers.
Standardized, price‑focused payments could limit clinician flexibility if narrow coverage rules or price‑based formularies replace individualized product selection.
Based on analysis of 3 sections of legislative text.
Official title: Amend title XVIII of the Social Security Act to reform the payment rules regarding skin substitute products.
Introduced July 31, 2025 by Bill Cassidy · Last progress July 31, 2025
Creates a single, consolidated Medicare payment method and billing code for skin substitute products beginning January 1, 2026. It sets the initial payment allowance as a volume-weighted average of prior ASP-based payment limits (using Oct–Dec 2023 billing data) and then updates that single payment annually by the change in CPI-U, while exempting skin substitute manufacturers from Medicare Average Sales Price reporting. Also clarifies that Medicare "reasonable and necessary" coverage rules continue to apply to skin substitutes except where safety concerns are identified and prohibits the Secretary from denying coverage solely on the basis of a clinical evidence analysis of a product.